Oncology

This is the latest episode of the free DDW podcast, “The pursuit of better cancer treatments”. It covers two narrated article written for Volume 22, Issue 3 –Summer 2021 of DDW. They are called “The personal touch: the scientist making an impact in cancer research” and “Biotech’s pursuit of next-generation CAR-T”.  In the first article, […]

This is the latest episode of the free DDW podcast, “The pursuit of better cancer treatments”. It covers two narrated article written for Volume 22, Issue 3 –Summer 2021 of DDW. They are called “The personal touch: the scientist making an impact in cancer research” and “Biotech’s pursuit of next-generation CAR-T”.  In the first article, […]

Early breast cancer patients in England will be able to access a new form of treatment following the recommendation for Eli Lilly’s abemaciclib by the National Institute of Health and Care Excellence (NICE).  The approval means that abemaciclib will be able to be used in combination with endocrine therapy in patients with hormone receptor-positive, HER2-negative, […]

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation to Novartis UK’s treatment for a specific type of cancer.  The authorisation was granted for Scemblix (asciminib), Novartis UK’s therapy for adults with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic phase (CP) who have previously been treated with two or more tyrosine […]

News round-up by DDW’s Reece Armstrong for 13-17 June. Partnerships, awards, and new companies are some of the topics of this week’s news round-up. Bachem & Eli Lilly partner on oligonucleotide project Swiss pharmaceutical company Bachem has partnered with Eli Lilly on a seven-year agreement to advance the development of oligonucleotide-based drug substances. KBI Biopharma & […]

A University of Cambridge spin-out has secured £2.4 million of investment to help it develop a pipeline of antibody drug conjugate (ADC) therapies for solid tumours.  Spirea is developing ACD therapeutics for solids tumours with a high unmet need. The company has developed technology that enables more cytotoxic drug to be attached to the targeting […]

Two life sciences companies have been awarded an €800K grant for their work developing a small molecule therapy for a fast-growing blood cancer.  Lead Pharma and Oxeltis were awarded the funding from EUREKA Eurostars for their three-year EPIGENEXT joint project.   Through the project, Lead Pharma and Oxeltis aim to develop a first-in-class small molecule therapy […]

Biopharmaceutical company Nurix Therapeutics has initiated the first of several potential Phase 1b expansion cohorts in its ongoing Phase 1 trial of its lead drug candidate targeting relapsed or refractory B-cell malignancies  The company’s lead candidate, NX-2127, is an orally administered degrader of Bruton’s tyrosine kinase (BTK) with immunomodulatory activity. Nurix had initially launched NX-2127 […]

This is the latest episode of the free DDW podcast, “Mini-library approach delivers an arsenal in drug development pipeline”. It covers a narrated article written for Volume 22, Issue 3 –Summer 2021 of DDW. In the article, Dr. Naganna Nimishetti, Chief of the Small Molecule Drug Discovery Division (SMDD) and Dr. Dun Yang, CEO/CSO of Anticancer […]

This is the latest episode of the free DDW podcast, “Mini-library approach delivers an arsenal in drug development pipeline”. It covers a narrated article written for Volume 22, Issue 3 –Summer 2021 of DDW. In the article, Dr. Naganna Nimishetti, Chief of the Small Molecule Drug Discovery Division (SMDD) and Dr. Dun Yang, CEO/CSO of Anticancer […]